https://www.selleckchem.com/
high prevalence of clarithromycin resistance (see Visual Abstract, Supplementary Digital Content 1, http//links.lww.com/CTG/A342). Anti-tumor necrosis factor (TNF) therapy is effective in inducing remission in Crohn's disease in 60% of patients. No serological biomarkers are available, which can predict response to anti-TNF. We aimed to investigate serological markers of collagen turnover reflecting tissue inflammation as predictors of response to anti-TNF. In 2 retrospective observational cohorts, markers for matrix metalloproteinase-degraded type III and
Like
Comment
Share
